Phenotypic and Genotypic Characterization of Fecal Escherichia Coli Isolates with Decreased Susceptibility to Fluoroquinolones: Results from a Large Hospital-based Surveillance Initiative
Overview
Authors
Affiliations
Background: The prevalence of fecal colonization with Escherichia coli that has reduced susceptibility to fluoroquinolones is unknown. A detailed characterization of such isolates is limited.
Methods: We conducted 3 annual fecal surveillance initiatives at 2 hospitals from 2002 to 2004. All E. coli isolates with reduced susceptibility to fluoroquinolones (minimum inhibitory concentration [MIC] to levofloxacin, > or = 0.125 microg/mL) were identified. We characterized gyrA and parC mutations and organic solvent tolerance (OST). Isolates were compared using pulsed-field gel electrophoresis.
Results: Of 789 fecal samples, 149 (18.9%) revealed E. coli with reduced susceptibility to fluoroquinolones. Of 149 isolates, 102 (68.5%) had a MIC > or = 8 microg/mL, 138 (92.6%) had > or = 1 gyrA mutation, 101 (67.8%) had > or = 1 parC mutation, and 59 (39.6%) demonstrated OST. Isolates with a MIC > or = 8 versus <8 microg/mL had more target mutations (median, 3 vs. 1; P<.001) and more often exhibited OST (51% vs. 15%; P<.001). Of 149 isolates, 144 (96.6%) demonstrated a MIC > or = 16 microg/mL to nalidixic acid. The prevalence of OST differed across study years (P = .01). There was no clonal spread of isolates.
Conclusions: Colonization by E. coli with reduced fluoroquinolone susceptibility is common, and fluoroquinolone-resistance characteristics differ significantly over time. Resistance to nalidixic acid may be useful in the identification of E. coli with early resistance mutations.
Update on bacterial pathogens: virulence and resistance.
Cercenado E, Garau J, Almirante B, Azanza J, Canton R, Cisterna R Enferm Infecc Microbiol Clin. 2024; 26:3-21.
PMID: 38620184 PMC: 7130156. DOI: 10.1016/S0213-005X(08)76378-X.
Han J, Garrigan C, Johnston B, Nachamkin I, Clabots C, Bilker W Diagn Microbiol Infect Dis. 2016; 87(3):275-280.
PMID: 27939288 PMC: 5292283. DOI: 10.1016/j.diagmicrobio.2016.11.016.
Anesi J, Lautenbach E, Nachamkin I, Garrigan C, Bilker W, Wheeler M Infect Control Hosp Epidemiol. 2016; 37(12):1433-1439.
PMID: 27678022 PMC: 5440186. DOI: 10.1017/ice.2016.225.
Liu H, Liu X, Li Y, Hao C World J Microbiol Biotechnol. 2015; 31(7):1041-8.
PMID: 25854862 DOI: 10.1007/s11274-015-1854-x.
Han J, Johnston B, Nachamkin I, Tolomeo P, Bilker W, Mao X Antimicrob Agents Chemother. 2014; 58(11):7003-6.
PMID: 25199782 PMC: 4249391. DOI: 10.1128/AAC.03256-14.